EVIPLERA (tenofovir disoproxil
rilpivirine), is now available on the
Pharmaceutical Benefits Scheme.
The medication is a complete
once-daily single tablet regimen
indicated for the treatment of HIV
infection in antiretroviral
treatment-naïve adults with plasma
HIV-1 RNA < 100,000 copies/mL at
the start of therapy.
The drug combines Truvada and
Janssen’s rilpivirine 25mg.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 29 May 12
Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country. MORE